



UNIVERSITAT DE
BARCELONA

Efectividad del concentrado de fibrinógeno en pacientes traumáticos con hemorragia crítica

Celia González Guerrero

ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR o al Repositorio Digital de la UB (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service and by the UB Digital Repository (diposit.ub.edu) has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized nor its spreading and availability from a site foreign to the TDX service or to the UB Digital Repository. Introducing its content in a window or frame foreign to the TDX service or to the UB Digital Repository is not authorized (framing). Those rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.



USE OF HUMAN FIBRINOGEN IN PATIENTS WITH HIGH-RISK OF SEVERE BLEEDING IN A TRAUMA HOSPITAL

González-Guerrero,C., Brandariz Núñez D., Mena Carmona D., Alcalde Rodrigo M., Juárez JC., Montoro, JB.
¹Pharmacy Unit. Hospital Universitari Vall d'Hebron. Barcelona. Spain

Background

Deficiency in human fibrinogen is a cause of massive haemorrhage whose management in emergency situations is the subject of debate.

Settings and Methods


In a third-level Trauma hospital, patients with a documented life-threatening haemorrhage who received a human fibrinogen prescription were included in the protocol, over a period of 12 months. Demographic data, treatment indication, Quick index, haemoglobin and haematocrit before and after treatment; admission diagnosis, fibrinogen dose and concomitant blood product treatment were collected.

Results

- ❖ 36 patients (69.57% ♂ and 30.43% ♀)
- ❖ Mean age: 55.23 years (range 18 – 85)
- ❖ Average dose: 2.39g
- ❖ Global survival after seven days: 86.96%
- ❖ 80.43% of patients had received surgery

Objective

Prospective, observational study, to ascertain how human fibrinogen is used in patients with life-threatening haemorrhagic disorders (trauma and surgery), especially in patients with underlying disease states that limit fibrinogen synthesis. Moreover, it aims to assess the adherence to the European guideline recommendations.



FIBRINOGEN PLASMA LEVELS			
	Plasma fibrinogen before administration (g/L)	Plasma fibrinogen after administration (g/L)	Adjustment to the European Clinical Guidelines
<2g/L	1.1	2.23	58.62 % adjusted
>2gr/L	2.83	2.78	41.38 % did not adjust

BLOOD PARAMETERS				
	Before administration	After administration	After 3 days	After 7 days
QT (s / % / INR)	21.73 / 68.88/ 1,62	19.20 / 75.96/ 1,38	18.35 / 79.96/ 1,36	17.35 / 84.71 / 1,29
aTTP (s)	41,29	32,22	35,17	32,32
Hb (g/dL)/ Ht (%)	9.37 / 27.46	9.63 / 28.02	9.77 / 28.44	-

Conclusions

- Among the patients studied it has been observed a notorious improvement in the coagulation parameters, as well as in the haemoglobin and haematocrit levels.
- Regarding to the European Clinical Guidelines, a 41.38% did not follow the recommendations as their fibrinogen initial levels were superior to 2gr/L.